Related Experiment Video
Updated: Jul 1, 2025
10:26
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
26.3K
Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in
Seung-June Oh1, Sung Tae Cho2, Hann-Chorng Kuo3
1Department of Urology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea.
Advances in Therapy
|March 2, 2024
Summary
Overactive bladder (OAB) treatments like mirabegron and antimuscarinics show high persistence rates. Effectiveness and persistence vary by OAB severity and prior treatment history.
Area of Science:
- Urology
- Pharmacology
- Clinical Trials
Background:
- Overactive bladder (OAB) significantly impacts quality of life.
- Understanding treatment patterns and persistence is crucial for effective OAB management.
Purpose of the Study:
- To assess OAB treatment patterns, effectiveness, and persistence with mirabegron versus antimuscarinics.
- To identify factors influencing treatment outcomes and patient adherence.
Main Methods:
- Prospective, longitudinal, observational registry study.
- Adults initiating OAB therapy with mirabegron or antimuscarinics were enrolled.
- Primary endpoints included treatment discontinuation/switching rates and reasons; secondary endpoints assessed symptom scores and safety.
Main Results:
- High persistence rates observed: over 60% of patients did not switch or discontinue treatment.
- Mirabegron showed better persistence in patients with mild/moderate OAB; antimuscarinics showed better persistence in those with prior OAB medication.
- Common adverse events included urinary tract infections (mirabegron) and dry mouth (antimuscarinics).
Conclusions:
- Mirabegron and antimuscarinics are frequently used first-line OAB therapies with substantial persistence.
- Treatment persistence is influenced by OAB severity and prior treatment experience.
- Further research can optimize OAB treatment strategies based on patient characteristics.
More Related Videos
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
169
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
169
01:26Cholinergic Antagonists: Therapeutic Uses
747
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
747
01:24Cholinergic Antagonists: Pharmacokinetics
439
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
439
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252
01:28Cholinergic Antagonists: Pharmacological Actions
1.1K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.1K
01:21Drugs for Treatment of Constipation-Predominant IBS
163
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
163